Fig. 3

miR-216b targets JMJD2C and inhibits its expression to enhance cisplatin-induced apoptosis in vitro. a miR-216b binding to JMJD2C was determined by the bioinformatics website Starbase in combination with the dual luciferase reporter assay in cells. agomir NC, miR-216b agomir, wt-JMJD2C-3’UTR and mut-JMJD2C-3’UTR were co-transfected into MG63 and SaOS-2 cells and then the luminescence intensity was determined. b Pearson correlation of miR-216b expression with JMJD2C expression in OS tissues (n = 60). c miR-216b expression and JMJD2C mRNA expression were determined by RT-qPCR in cells, relative to U6 and β-actin, respectively, and representative Western blots of JMJD2C protein and its quantitation in cells, relative to β-actin. d Cell viability in MG63 and SaOS-2 cells was determined by CCK-8 assay. e Apoptosis of MG63 and SaOS-2 cells was determined by flow cytometry. * p < 0.05 vs. cells treated with agomir NC + oe-NC, # p < 0.05 vs. cells treated with miR-216b agomir + oe-NC. Data in panel (a) were compared by unpaired t-test, in panel (c) and (e) using one-way ANOVA, with Tukey’s test and in panel (b) by repeated measures ANOVA with Bonferroni test. Data are shown as mean ± standard deviation of three technical replicates